A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury.
Phase of Trial: Phase II/III
Latest Information Update: 16 Jul 2017
At a glance
- Drugs VX 210 (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 31 Mar 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 29 Jan 2016 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
- 13 Jan 2016 New trial record